USD
$0.00
(0.00%
)At Close (As of Aug 29, 2025)
$4.38B
Market Cap
19.54
P/E Ratio
1.33
EPS
$26.65
52 Week High
$13.40
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | $876M |
Total Revenue | $958M |
Cost Of Revenue | $82M |
Costof Goods And Services Sold | $82M |
Operating Income | $231M |
Selling General And Administrative | $488M |
Research And Development | $303M |
Operating Expenses | $645M |
Investment Income Net | - |
Net Interest Income | $25M |
Interest Income | $25M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $16M |
Income Before Tax | $258M |
Income Tax Expense | $32M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $226M |
Comprehensive Income Net Of Tax | - |
Ebit | $84M |
Ebitda | $100M |
Net Income | $226M |
Field | Value (USD) |
---|---|
Total Assets | $1.2B |
Total Current Assets | $938M |
Cash And Cash Equivalents At Carrying Value | $320M |
Cash And Short Term Investments | $320M |
Inventory | $22M |
Current Net Receivables | $105M |
Total Non Current Assets | $249M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $120M |
Intangible Assets Excluding Goodwill | $120M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $436M |
Other Current Assets | $56M |
Other Non Current Assets | - |
Total Liabilities | $455M |
Total Current Liabilities | $395M |
Current Accounts Payable | $16M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $10M |
Total Non Current Liabilities | $60M |
Capital Lease Obligations | $52M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $52M |
Other Current Liabilities | $299M |
Other Non Current Liabilities | $18M |
Total Shareholder Equity | $733M |
Treasury Stock | - |
Retained Earnings | -$2.2B |
Common Stock | $16K |
Common Stock Shares Outstanding | $166M |
Field | Value (USD) |
---|---|
Operating Cashflow | $158M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $16M |
Capital Expenditures | $523K |
Change In Receivables | - |
Change In Inventory | -$50M |
Profit Loss | - |
Cashflow From Investment | -$31M |
Cashflow From Financing | $6.8M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $226M |
Field | Value (USD) |
---|---|
Gross Profit | $876M |
Total Revenue | $958M |
Cost Of Revenue | $82M |
Costof Goods And Services Sold | $82M |
Operating Income | $231M |
Selling General And Administrative | $488M |
Research And Development | $303M |
Operating Expenses | $645M |
Investment Income Net | - |
Net Interest Income | $25M |
Interest Income | $25M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $16M |
Income Before Tax | $258M |
Income Tax Expense | $32M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $226M |
Comprehensive Income Net Of Tax | - |
Ebit | $84M |
Ebitda | $100M |
Net Income | $226M |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.